For decades, LDL-C has been the default target guiding statin therapy decisions, yet mounting evidence suggests it misses meaningful residual cardiovascular risk in treated patients. This economic modeling study from JAMA asks a more actionable question: not just which lipid marker is biologically superior, but whether switching clinical targets is actually worth the cost — a distinction that could reshape how millions of adults are managed for primary prevention.
Using a computer simulation of 250,000 statin-eligible, cardiovascular disease-free U.S. adults built from NHANES data (2005–2016, n = 4,149), researchers compared the cost-effectiveness of intensifying lipid-lowering therapy — with high-intensity statins or ezetimibe — according to three treatment targets: LDL-C below 100 mg/dL, non-HDL-C below 118 mg/dL, and apoB below 78 mg/dL. Model inputs drew from pooled longitudinal cohort data and published literature, with extensive sensitivity analyses to probe uncertainty. The apoB-guided strategy emerged as the most cost-effective approach for treatment intensification in primary prevention, outperforming both LDL-C and non-HDL-C thresholds on standard health-economic benchmarks.
This finding carries real clinical weight. ApoB directly counts atherogenic lipoprotein particles — including small, dense LDL and VLDL remnants — that standard LDL-C calculations can underestimate, particularly in patients with metabolic syndrome or hypertriglyceridemia. The superiority of apoB as a residual risk marker has been established in observational literature, but economic justification has been largely absent from guideline discussions. That gap now has a data point. Important limitations apply: simulation models depend heavily on assumed input parameters, and this is a modeling exercise rather than a randomized trial. ApoB testing remains less routinely available and less standardized globally than LDL-C. Still, as ezetimibe becomes increasingly generic and affordable, the marginal cost of intensification falls — making apoB-guided decisions incrementally more attractive. This study is best read as confirmatory and directionally significant rather than paradigm-shifting on its own.